By Donato Paolo Mancini

Sanofi SA's (SAN.FR) and Regeneron Pharmaceuticals Inc.'s (REGN) Dupixent has met all primary and secondary endpoints in two phase 3 placebo-controlled trials, Sanofi said Tuesday.

The trials were for adults with inadequately-controlled chronic rhinosinusitis with nasal polyps.

At 24 weeks, patients in the two studies treated with the drug experienced a 51% and 57% improvement in nasal congestion respectively, a primary endpoint, compared with 15% and 19% with nasal spray alone, or with the placebo, the company said.

Dupixent also met all secondary endpoints in both trials, including reducing the need for surgery, Sanofi said.

Write to Donato Paolo Mancini at donatopaolo.mancini@dowjones.com; @donatopmancini

(END) Dow Jones Newswires

October 16, 2018 01:29 ET (05:29 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Sanofi Charts.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Sanofi Charts.